Bellerophon Therapeutics Announces Interim Results of Nitric Oxide Clinical Trial in Pulmonary Arterial Hypertension

2018-08-10T21:02:47+00:00 August 10th, 2018|

Bellerophon Therapeutics announced this week that its Phase 3 clinical trial of pulsatile inhaled nitric oxide (iNO) for World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or PAH) was discontinued for futility August 7, after a planned interim analysis. Nitric oxide (NO) is a molecule naturally produced in the body that helps many

Fatigue: Under-Recognized and Unaddressed in PH

2018-08-10T21:01:47+00:00 August 10th, 2018|

by Phyllis Hanlon, Contributing Writer Symptoms that are commonly experienced by people with pulmonary hypertension (PH) — such as shortness of breath, light-headedness, chest pain, swelling and fatigue — can negatively impact their quality of life. Fatigue – lack of energy or an increased sense of effort with routine tasks – is reported in

Participation in PHA Conference Opens Doors for Northwestern University Researcher

2018-07-27T17:41:33+00:00 July 27th, 2018|

Zhiyu Dai, Ph.D., a researcher at Northwestern University and assistant professor of research at Northwestern University Feinberg School of Medicine in Chicago, has presented his work during the past two Pulmonary Hypertension Association (PHA) International PH Conference and Scientific Sessions. He also has been awarded top abstract in basic science by the Scientific Sessions

Rare Disease Caregiving Report Paints a Portrait of PH Caregivers in the U.S.

2018-07-06T21:06:10+00:00 July 6th, 2018|

This article by Mike Knaapen, Director, Patient and Caregiver Programs and Lisa Weber, Vice President, Greenwald and Associates, first appeared in Issue 2 2018 of Pathlight magazine. Become a member of PHA to receive this quarterly publication full of patient profiles, medical information and tips for living with pulmonary hypertension. It is well known

Conference Speaker Spotlight: Norman Stockbridge, M.D., Ph.D.

2018-06-20T16:00:31+00:00 June 20th, 2018|

The Pulmonary Hypertension Association (PHA) Scientific Sessions Planning Committee has announced Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products (DCaRP) in the Center for Drug Evaluation and Research of the Food and Drug Administration (FDA), as a speaker at PHA’s 2018 International PH Conference and Scientific Sessions. DCaRP is responsible

Conference Speaker Spotlight: Sagar Lonial, M.D., FACP

2018-06-15T20:23:38+00:00 June 15th, 2018|

Prompted by recent successes in the field of oncology in precision medicine, the Pulmonary Hypertension Association’s (PHA) Scientific Sessions Committee has invited Sagar Lonial, M.D., FACP, an internationally-recognized leading authority in multiple myeloma treatment and research, to provide his insight in the field of PH to health care providers. Dr. Lonial’s research has focused

PHA-Funded Research Discovers Link Between Cancer Protein and Fibrosis in PAH Patients

2018-06-15T20:26:20+00:00 June 15th, 2018|

A new molecular mechanism in the development of World Health Organization (WHO) Group 1 pulmonary hypertension (PH) – pulmonary arterial hypertension (PAH) – has been discovered by investigators from the Brigham and Women’s Hospital, through work funded in part by the Pulmonary Hypertension Association (PHA). NEDD9, a protein that was discovered in 1992 and has

Pediatric Focus at PHA’s 2018 International PH Conference and Scientific Sessions

2018-06-08T19:19:29+00:00 June 7th, 2018|

Steven H. Abman, M.D. David B. Frank, M.D., Ph.D. Stephanie Siehr Handler, M.D. Uyen Truong, M.D. Erika S. Berman Rosenzweig, M.D. Despite recent milestones in the field of pediatric PH, knowledge and treatment options still lag behind that of adult PH. This year’s

Conference Speaker Spotlight: Michael Snyder, Ph.D.

2018-06-01T17:00:29+00:00 May 21st, 2018|

Because genetics are essential to the discussion about precision medicine, the Scientific Sessions Committee is excited to feature Michal Snyder, Ph.D., Stanford Ascherman professor and chair of Genetics and director of the Center of Genomics and Personalized Medicine at Stanford University School of Medicine, during the session block “Omics and Wearable in Pulmonary Hypertension:

Early Intervention: Better Clinical and Economic Outcomes

2018-05-09T18:26:10+00:00 May 9th, 2018|

by Phyllis Hanlon, Contributing Writer   Researchers who study WHO Group 1 PH (PAH, pulmonary arterial hypertension) have shown that drugs may delay progression of the disease, reduce symptoms and improve quality of life. More recently, scientists have found that using more than one drug early when a patient is newly diagnosed can produce an even